Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Account Payables (2021 - 2025)

Prime Medicine (PRME) has disclosed Change in Account Payables for 5 consecutive years, with -$581000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 123.62% year-over-year to -$581000.0, compared with a TTM value of $996000.0 through Dec 2025, up 118.95%, and an annual FY2025 reading of $996000.0, up 118.95% over the prior year.
  • Change in Account Payables was -$581000.0 for Q4 2025 at Prime Medicine, down from $3.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.8 million in Q3 2023 and bottomed at -$5.9 million in Q1 2024.
  • Average Change in Account Payables over 5 years is $436294.1, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Change in Account Payables surged 1535.66% in 2023, then crashed 1066.67% in 2024.
  • Year by year, Change in Account Payables stood at $80000.0 in 2021, then surged by 438.75% to $431000.0 in 2022, then surged by 428.77% to $2.3 million in 2023, then grew by 7.94% to $2.5 million in 2024, then plummeted by 123.62% to -$581000.0 in 2025.
  • Business Quant data shows Change in Account Payables for PRME at -$581000.0 in Q4 2025, $3.0 million in Q3 2025, and -$3.3 million in Q2 2025.